Literature DB >> 23255589

TLR3 deficiency induces chronic inflammatory cardiomyopathy in resistant mice following coxsackievirus B3 infection: role for IL-4.

Eric D Abston1, Michael J Coronado, Adriana Bucek, Jennifer A Onyimba, Jessica E Brandt, J Augusto Frisancho, Eunyong Kim, Djahida Bedja, Yoon-kyu Sung, Andrea J Radtke, Kathleen L Gabrielson, Wayne Mitzner, DeLisa Fairweather.   

Abstract

Recent findings indicate that TLR3 polymorphisms increase susceptibility to enteroviral myocarditis and inflammatory dilated cardiomyopathy (iDCM) in patients. TLR3 signaling has been found to inhibit coxsackievirus B3 (CVB3) replication and acute myocarditis in mouse models, but its role in the progression from myocarditis to iDCM has not been previously investigated. In this study we found that TLR3 deficiency increased acute (P = 5.9 × 10(-9)) and chronic (P = 6.0 × 10(-7)) myocarditis compared with WT B6.129, a mouse strain that is resistant to chronic myocarditis and iDCM. Using left ventricular in vivo hemodynamic assessment, we found that TLR3-deficient mice developed progressively worse chronic cardiomyopathy. TLR3 deficiency significantly increased viral replication in the heart during acute myocarditis from day 3 through day 12 after infection, but infectious virus was not detected in the heart during chronic disease. TLR3 deficiency increased cytokines associated with a T helper (Th)2 response, including IL-4 (P = 0.03), IL-10 (P = 0.008), IL-13 (P = 0.002), and TGF-β(1) (P = 0.005), and induced a shift to an immunoregulatory phenotype in the heart. However, IL-4-deficient mice had improved heart function during acute CVB3 myocarditis by echocardiography and in vivo hemodynamic assessment compared with wild-type mice, indicating that IL-4 impairs cardiac function during myocarditis. IL-4 deficiency increased regulatory T-cell and macrophage populations, including FoxP3(+) T cells (P = 0.005) and Tim-3(+) macrophages (P = 0.004). Thus, TLR3 prevents the progression from myocarditis to iDCM following CVB3 infection by reducing acute viral replication and IL-4 levels in the heart.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23255589      PMCID: PMC3567355          DOI: 10.1152/ajpregu.00516.2011

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  58 in total

1.  Regulatory T cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor beta-coxsackie-adenovirus receptor pathway.

Authors:  Yu Shi; Masahiro Fukuoka; Guohua Li; Youan Liu; Manyin Chen; Michael Konviser; Xin Chen; Mary Anne Opavsky; Peter P Liu
Journal:  Circulation       Date:  2010-06-07       Impact factor: 29.690

Review 2.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

Review 3.  Influenza-related viral myocarditis.

Authors:  Shereif H Rezkalla; Robert A Kloner
Journal:  WMJ       Date:  2010-08

Review 4.  Inflammatory dilated cardiomyopathy (DCMI).

Authors:  Bernhard Maisch; Anette Richter; Andrea Sandmöller; Irene Portig; Sabine Pankuweit
Journal:  Herz       Date:  2005-09       Impact factor: 1.443

Review 5.  Cardiomyopathy: an overview.

Authors:  Randell K Wexler; Terry Elton; Adam Pleister; David Feldman
Journal:  Am Fam Physician       Date:  2009-05-01       Impact factor: 3.292

6.  Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy.

Authors:  G Christian Baldeviano; Jobert G Barin; Monica V Talor; Sachin Srinivasan; Djahida Bedja; Dongfeng Zheng; Kathleen Gabrielson; Yoichiro Iwakura; Noel R Rose; Daniela Cihakova
Journal:  Circ Res       Date:  2010-04-08       Impact factor: 17.367

7.  Contribution of TLR7 and TLR9 signaling to the susceptibility of MyD88-deficient mice to myocarditis.

Authors:  Philippe P Pagni; Stephanie Traub; Olivier Demaria; Lionel Chasson; Lena Alexopoulou
Journal:  Autoimmunity       Date:  2010-06       Impact factor: 2.815

8.  Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart.

Authors:  DeLisa Fairweather; Sylvia Frisancho-Kiss; Susy A Yusung; Masheka A Barrett; Sarah E Davis; Shannon J L Gatewood; Dolores B Njoku; Noel R Rose
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Remission of CVB3-induced viral myocarditis by in vivo Th2 polarization via hydrodynamics-based interleukin-4 gene transfer.

Authors:  Zhenggang Jiang; Wei Xu; Kang Li; Yan Yue; Lin Xu; Fei Ye; Sidong Xiong
Journal:  J Gene Med       Date:  2008-08       Impact factor: 4.565

10.  The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice.

Authors:  Jennifer A Onyimba; Michael J Coronado; Amanda E Garton; Joseph B Kim; Adriana Bucek; Djahida Bedja; Kathleen L Gabrielson; Tomas R Guilarte; DeLisa Fairweather
Journal:  Biol Sex Differ       Date:  2011-02-21       Impact factor: 5.027

View more
  17 in total

1.  Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension.

Authors:  Daniela Farkas; A A Roger Thompson; Aneel R Bhagwani; Schuyler Hultman; Hyun Ji; Naveen Kotha; Grant Farr; Nadine D Arnold; Adam Braithwaite; Helen Casbolt; Jennifer E Cole; Ian Sabroe; Claudia Monaco; Carlyne D Cool; Elena A Goncharova; Allan Lawrie; Laszlo Farkas
Journal:  Am J Respir Crit Care Med       Date:  2019-01-15       Impact factor: 21.405

2.  Immunological and pathological consequences of coxsackievirus RNA persistence in the heart.

Authors:  Claudia T Flynn; Taishi Kimura; Kwesi Frimpong-Boateng; Stephanie Harkins; J Lindsay Whitton
Journal:  Virology       Date:  2017-12       Impact factor: 3.616

Review 3.  Complexities in the relationship between infection and autoimmunity.

Authors:  Robert Root-Bernstein; DeLisa Fairweather
Journal:  Curr Allergy Asthma Rep       Date:  2014-01       Impact factor: 4.806

4.  Enterovirus 68 3C protease cleaves TRIF to attenuate antiviral responses mediated by Toll-like receptor 3.

Authors:  Zichun Xiang; Linlin Li; Xiaobo Lei; Hongli Zhou; Zhuo Zhou; Bin He; Jianwei Wang
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

Review 5.  Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.

Authors:  Antoine Bondue; Eloisa Arbustini; Anna Bianco; Michele Ciccarelli; Dana Dawson; Matteo De Rosa; Nazha Hamdani; Denise Hilfiker-Kleiner; Benjamin Meder; Adelino F Leite-Moreira; Thomas Thum; Carlo G Tocchetti; Gilda Varricchi; Jolanda Van der Velden; Roddy Walsh; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

Review 6.  Interleukin 4: Its Role in Hypertension, Atherosclerosis, Valvular, and Nonvalvular Cardiovascular Diseases.

Authors:  Kamal M Kassem; Mahboob Ali; Nour-Eddine Rhaleb
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-08-11       Impact factor: 2.457

7.  In vivo ablation of type I interferon receptor from cardiomyocytes delays coxsackieviral clearance and accelerates myocardial disease.

Authors:  Nadine Althof; Stephanie Harkins; Christopher C Kemball; Claudia T Flynn; Mehrdad Alirezaei; J Lindsay Whitton
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

Review 8.  Enter at your own risk: how enteroviruses navigate the dangerous world of pattern recognition receptor signaling.

Authors:  Katharine G Harris; Carolyn B Coyne
Journal:  Cytokine       Date:  2013-06-10       Impact factor: 3.861

Review 9.  Sex differences in inflammation during atherosclerosis.

Authors:  DeLisa Fairweather
Journal:  Clin Med Insights Cardiol       Date:  2015-04-19

Review 10.  Sex Differences, Genetic and Environmental Influences on Dilated Cardiomyopathy.

Authors:  Angita Jain; Nadine Norton; Katelyn A Bruno; Leslie T Cooper; Paldeep S Atwal; DeLisa Fairweather
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.